Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by PoorOpinionon Nov 02, 2018 1:24am

124 Views

Post# 28912441

RE:Full Fostemsavir study data

Presented at the Glasgow conf Theratech were at.

Abstracts are here.

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jia2.25187

Abstracts O344a and O344b on page 20 of the PDF (doc page 17) or fostemvir data. Just before ibalizumab abstract O345.

According to the Ibalizumab abstract only 27 patients rolled over from the trial to the EAP and only 24 continued through. Presumably only these went on to be payors. I was thinking more.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale